A list of downloadable documents created during development.

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. We can accept comments from individuals. These will be considered, but you won’t get a formal ...

Health inequalities modular update to NICE health technology evaluations: the manual (PMG36) Methods / process manual consultation NICE process and methods 31 January 2025 Highly specialised ...

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...

Adults may need support to manage their medicines safely and effectively, and for some people this will be provided as part of a home care service. When medicines support starts, tell the person’s GP ...

Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Suggested remit: To appraise the clinical and cost effectiveness of Semaglutide within its marketing authorisation for treating cardiovascular disease.

have completed their Master of Public health (MPH) or individuals undertaking the portfolio route must have either passed their DFPH (Faculty of Public Health Diplomate Examination, formally Part A ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...